Recent advances in cardiovascular research increasingly recognize the gut microbiome as a pivotal factor influencing cardiovascular disease (CVD) pathogene | Drug Discovery And Development ...

TERN-101 is a potent, non-bile acid farnesoid X receptor (FXR) agonist. FXR activation has been shown to prevent the progression from histological liver fibrosis to NASH.

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders. A recent study has ...

Farnesoid X receptor is a member of the ligand-activated nuclear hormone receptor superfamily. It functions as heterodimer with retinoid X receptor and binds genomic DNA of the target genes ...

Please provide your email address to receive an email when new articles are posted on . FXR314-treated patients achieved up to 22.8% reduction in liver fat content at 16 weeks vs. 6.1% with ...

In a recent study published in Nature, researchers assessed the association between farnesoid X receptor (FXR) inhibition and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Therapeutic strategies targeting this pathway include peroxisome proliferator-activated receptor (PPAR) agonists, bile acid-farnesoid X receptor (FXR) agonists, and de novo lipogenesis (DNL) ...

Through the acquisition, Equillium adds Metacrine’s farnesoid X receptor (FXR) platform, including lead molecule MET642, an orally delivered FXR agonist that is a potential first-in-class, non ...

After reviewing data from its phase II trial of farnesoid X receptor agonist ASC-42 in primary biliary cholangitis, Ascletis Pharma Inc. said it was quitting development of the molecule in all ...

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders. In a study published in ...